Abstract
The blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) form a very effective barrier to the free diffusion of many polar solutes into the brain. Many metabolites that are polar have their brain entry facilitated by specific inwardly-directed transport mechanisms. In general the more lipid soluble a molecule or drug is, the more readily it will tend to partition into brain tissue. However, a very significant number of lipid soluble molecules, among them many useful therapeutic drugs have lower brain permeability than would be predicted from a determination of their lipid solubility. These molecules are substrates for the ABC efflux transporters which are present in the BBB and BCSB and the activity of these transporters very efficiently removes the drug from the CNS, thus limiting brain uptake. Pglycoprotein (Pgp) was the first of these ABC transporters to be described, followed by the multidrug resistanceassociated proteins (MRP) and more recently breast cancer resistance protein (BCRP). All are expressed in the BBB and BCSFB and combine to reduce the brain penetration of many drugs. This phenomenon of “multidrug resistance” is a major hurdle when it comes to the delivery of therapeutics to the brain, not to mention the problem of cancer chemotherapy in general. Therefore, the development of strategies for bypassing the influence of these ABC transporters and for the design of effective drugs that are not substrates and the development of inhibitors for the ABC transporters becomes a high imperative for the pharmaceutical industry.
Keywords: abc transporters, blood-brain barrier, blood-cerebrospinal fluid barrier
Current Pharmaceutical Design
Title: ABC Transporters and the Blood-Brain Barrier
Volume: 10 Issue: 12
Author(s): David J. Begley
Affiliation:
Keywords: abc transporters, blood-brain barrier, blood-cerebrospinal fluid barrier
Abstract: The blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) form a very effective barrier to the free diffusion of many polar solutes into the brain. Many metabolites that are polar have their brain entry facilitated by specific inwardly-directed transport mechanisms. In general the more lipid soluble a molecule or drug is, the more readily it will tend to partition into brain tissue. However, a very significant number of lipid soluble molecules, among them many useful therapeutic drugs have lower brain permeability than would be predicted from a determination of their lipid solubility. These molecules are substrates for the ABC efflux transporters which are present in the BBB and BCSB and the activity of these transporters very efficiently removes the drug from the CNS, thus limiting brain uptake. Pglycoprotein (Pgp) was the first of these ABC transporters to be described, followed by the multidrug resistanceassociated proteins (MRP) and more recently breast cancer resistance protein (BCRP). All are expressed in the BBB and BCSFB and combine to reduce the brain penetration of many drugs. This phenomenon of “multidrug resistance” is a major hurdle when it comes to the delivery of therapeutics to the brain, not to mention the problem of cancer chemotherapy in general. Therefore, the development of strategies for bypassing the influence of these ABC transporters and for the design of effective drugs that are not substrates and the development of inhibitors for the ABC transporters becomes a high imperative for the pharmaceutical industry.
Export Options
About this article
Cite this article as:
Begley J. David, ABC Transporters and the Blood-Brain Barrier, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384844
DOI https://dx.doi.org/10.2174/1381612043384844 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Cancer Agents Synthesis and SAR Study of Prenylated Xanthone Analogues as HeLa and MDA-MB-231 Cancer Cell Inhibitors
Letters in Drug Design & Discovery Pharmacogenomics of Human ABC Transporter ABCC11 (MRP8): Potential Risk of Breast Cancer and Chemotherapy Failure
Anti-Cancer Agents in Medicinal Chemistry ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Malnutrition in Patients with End-Stage Renal Disease - Anorexia,Cachexia and Catabolism
Current Nutrition & Food Science SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
Current Drug Delivery Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis
Current Gene Therapy A Comparative Study of the Cytotoxic and Pro-apoptotic Properties of Nepeta binaloudensis
Letters in Drug Design & Discovery Overview of Naphthalimide Analogs as Anticancer Agents
Current Medicinal Chemistry Mucin-based Targeted Pancreatic Cancer Therapy
Current Pharmaceutical Design Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry RNAi in Plasmodium
Current Pharmaceutical Design Analytic strategies to evaluate the association of time-varying exposures to HIV-related outcomes: Alcohol consumption as an example
Current HIV Research Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets